SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LaBrosse Nicole

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

11388 SORRENTO VALLEY ROAD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/02/2022

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,033	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	07/01/2016⁽¹⁾	07/01/2025	Common Stock	35,000	$22.5	D
Option to Purchase Common Stock	02/22/2018⁽¹⁾	02/22/2027	Common Stock	11,271	$12.07	D
Option to Purchase Common Stock	08/01/2018⁽¹⁾	08/01/2027	Common Stock	1,947	$12.49	D
Option to Purchase Common Stock	02/14/2019⁽¹⁾	02/14/2028	Common Stock	8,813	$18.41	D
Option to Purchase Common Stock	02/12/2020⁽¹⁾	02/12/2029	Common Stock	10,597	$16.65	D
Option to Purchase Common Stock	02/10/2021⁽¹⁾	02/10/2030	Common Stock	21,285	$19.98	D
Option to Purchase Common Stock	02/15/2022⁽¹⁾	02/15/2031	Common Stock	12,951	$49.84	D
Restricted Stock Unit	02/14/2019⁽²⁾	⁽²⁾	Common Stock	1,256	⁽²⁾	D
Restricted Stock Unit	02/12/2020⁽²⁾	⁽²⁾	Common Stock	2,778	⁽²⁾	D
Restricted Stock Unit	02/10/2021⁽²⁾	⁽²⁾	Common Stock	7,508	⁽²⁾	D
Restricted Stock Unit	02/15/2022⁽²⁾	⁽²⁾	Common Stock	5,017	⁽²⁾	D

Explanation of Responses:

1. This option vests one-fourth on such date and then 1/48th monthly thereafter.

2. One-fourth of the original grant vests on such date and then one-fourth annually thereafter. Represents a restricted stock unit award with no exercise price.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ James R. Oehler as attorney-in-fact for Nicole LaBrosse	02/11/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.